Potential COVID‐19 therapeutic approaches targeting angiotensin‐converting enzyme 2; An updated review.

Summary: COVID‐19 has spread swiftly throughout the world posing a global health emergency. The significant numbers of deaths attributed to this pandemic have researchers battling to understand this new, dangerous virus. Researchers are looking to find possible treatment regimens and develop effective therapies. This study aims to provide an overview of published scientific information on potential treatments, emphasizing angiotensin‐converting enzyme II (ACE2) inhibitors as one of the most important drug targets. SARS‐CoV‐2 receptor‐binding domain (RBD); as a viral attachment or entry inhibitor against SARS‐CoV‐2, human recombinant soluble ACE2; as a genetically modified soluble form of ACE2 to compete with membrane‐bound ACE2, and microRNAs (miRNAs); as a negative regulator of the expression of ACE2/TMPRSS2 to inhibit SARS‐CoV2 entry into cells, are the potential therapeutic approaches discussed thoroughly in this article. This review provides the groundwork for the ongoing development of therapeutic agents and effective treatments against SARS‐COV‐2. [ABSTRACT FROM AUTHOR]